BRGX — BioRegenx Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapNeutral

Annual income statement for BioRegenx, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2012 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PRESS	10-K	10-K	10-K	10-K
Standards:	—	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	8.08	0.404	0.199	0.042	0.022
Cost of Revenue
Gross Profit	1.03	0.318	0.087	0.032	0.022
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	9.84	0.678	0.364	0.12	0.585
Operating Profit	-1.76	-0.274	-0.165	-0.078	-0.563
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-1.75	-0.274	-0.097	-0.078	-0.571
Provision for Income Taxes
Net Income After Taxes	-1.75	-0.274	-0.097	-0.078	-0.571
Minority Interest
Net Income Before Extraordinary Items
Net Income	-1.75	-0.274	-0.097	-0.078	-0.571
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	-1.75	-0.274	-0.097	-0.078	-0.571
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-0.018	-0.001	-0	-0	-0
Dividends per Share